Pascual, M., Nieto, A., Lopez-Nevot, M.A., Ramal, L., Mataran, L., Caballero, A., et al. (2001) Rheumatoid Arthritis in Southern Spain: Toward Elucidation of a Unifying Role of the HLA Class II Region in Disease Predisposition. Arthritis & Rheumatology, 44, 307-314.
https://doi.org/10.1002/1529-0131(200102)44:2<307::AID-ANR47>3.0.CO;2-K

has been cited by the following article:

• TITLE: Challenges of Rheumatoid Arthritis Management in Sub-Saharan Africa in the 21st Century

  AUTHORS: Malewe Kolou

  KEYWORDS: Rheumatoid Arthritis, Black Africa, Rheumatoid Factor, Anti-Cyclic Citrullinated Peptide Antibodies

  JOURNAL NAME: Open Journal of Rheumatology and Autoimmune Diseases, Vol.13 No.1, February 9, 2023

  ABSTRACT: In recent decades, several advances have been made in the management of rheumatoid arthritis (RA) both in the diagnostic field and in the therapeutic field. Unfortunately, RA remains poorly studied in black Africa. Epidemiological data are rare and controversial. The estimated prevalence of RA in Africa is about 0% - 2.54%. Risk factors associated with RA must be studied by taking into account special features of black Africa such as the low tobacco consumption in certain regions, the tropical climate and the high frequency of endemic parasitic and viral infections. The initially supposed mildness of RA in black Africa is increasingly challenged. The diagnosis is often made too late because of the scarcity of rheumatologists and ignorance. Diagnostic tools are limited to the clinical data, the erythrocyte sedimentation rate and radiographs as the other tools are poorly available. In addition, there are misconceptions in African communities, responsible for loss of sight during follow-up and treatment discontinuations. This is exacerbated by the shortage of disease-modifying anti-rheumatic drugs (DMARDs) and the inability to afford them. Furthermore, biological agents are very difficult to access. Further studies are essential to better understand the characteristics of RA in black Africa. Thus, collaborations between African and Western research teams seem very important. In order to make available the DMARDs especially biological agents, pharmaceutical companies can contribute through research partnerships. Moreover, governments should provide a better place for chronic inflammatory diseases in the programs against non-communicable diseases. Finally, training must also be promoted to increase the number of specialists and the level of knowledge of other health workers.